Onbrez 300mcg Breezhaler contains indacaterol, a long-acting beta2-adrenergic receptor agonist (LABA) indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Indacaterol provides sustained bronchodilation by selectively stimulating beta2-adrenergic receptors in the airway smooth muscle, resulting in relaxation and improved airflow. The 300mcg dose is delivered via the Breezhaler device, designed to ensure efficient pulmonary deposition and ease of use. Onbrez is intended for once-daily administration to improve lung function, reduce symptoms such as breathlessness, and enhance exercise tolerance in patients with COPD. It is not indicated for the relief of acute bronchospasm or asthma treatment. The onset of action is rapid, with effects lasting at least 24 hours, supporting adherence through convenient dosing. Common adverse effects may include nasopharyngitis, cough, and headache, while serious side effects, although rare, can involve cardiovascular events or paradoxical bronchospasm. Onbrez should be used with caution in patients with cardiovascular disorders and is contraindicated in patients with hypersensitivity to indacaterol or any excipients. Regular monitoring of lung function and symptom control is recommended to optimize therapy.